Atherosclerosis
Volume 202, Issue 2 , Pages 543-549 , February 2009

Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease

  • Christian Murr

      Affiliations

    • Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria
    • ,
  • Brigitte M. Winklhofer-Roob

      Affiliations

    • Human Nutrition & Metabolism Research and Training Center, Institute of Molecular Biosciences, Karl-Franzens University, Graz, Austria
    • ,
  • Katharina Schroecksnadel

      Affiliations

    • Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria
    • Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria
    • ,
  • Michaela Maritschnegg

      Affiliations

    • Human Nutrition & Metabolism Research and Training Center, Institute of Molecular Biosciences, Karl-Franzens University, Graz, Austria
    • ,
  • Harald Mangge

      Affiliations

    • Clinical Department of Medical and Chemical Laboratory Diagnostics, Graz Medical University, Graz, Austria
    • ,
  • Bernhard O. Böhm

      Affiliations

    • Division of Endocrinology, Department of Medicine, University Hospital, Ulm, Germany
    • ,
  • Bernhard R. Winkelmann

      Affiliations

    • Cardiology Group Sachsenhausen, Frankfurt am Main, Germany
    • ,
  • Winfried März

      Affiliations

    • Synlab Center of Laboratory Diagnostics, Heidelberg, Germany
    • ,
  • Dietmar Fuchs

      Affiliations

    • Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 512 9003 70350; fax: +43 512 9003 73330.

Received 23 November 2007 ,Revised 25 April 2008 ,Accepted 30 April 2008.

References 

  1. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J Exp Med. 1984;160:310–316
  2. Wirleitner B, Reider D, Ebner S, et al. Monocyte-derived dendritic cells release neopterin. J Leukoc Biol. 2002;72:1148–1153
  3. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab. 2002;3:175–187
  4. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation; inflammatory; infectious and malignant diseases. Crit Rev Clin Lab Sci. 1992;29:307–341
  5. Samsonov MY, Tilz GP, Egorova O, et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus. 1985;4:29–32
  6. Murr C, Bergant A, Widschwendter M, Heim K, Schröcksnadel H, Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem. 1999;45:1998–2004
  7. Reibnegger G, Aichberger C, Fuchs D, et al. Posttransplant neopterin excretion in renal allograft recipients: reliable diagnostic aid of acute rejection and predictive marker of long-term survival. Transplantation. 1991;52:58–63
  8. Tatzber F, Rabl H, Koriska K, et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis. 1991;89:203–208
  9. Weiss G, Willeit J, Kiechl S, et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis. 1994;106:263–271
  10. Schumacher M, Halwachs G, Tatzber F, et al. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol. 1997;30:703–707
  11. Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Mautner B. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 1999;83:515–518
  12. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185–192
  13. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004;110:1747–1753
  14. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J. 2005;26:457–463
  15. Johnston DT, Gagos M, Raio N, et al. Alterations in serum neopterin correlate with thrombolysis in myocardial infarction risk scores in acute coronary syndromes. Coron Artery Dis. 2006;17:511–516
  16. Ray KK, Morrow DA, Sabatine MS, et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation. 2007;115:3071–3078
  17. Adachi T, Naruko T, Itoh A, et al. Neopterin is associated with plaque inflammation and destabilization in human coronary atherosclerotic lesions. Heart. 2007;93:1537–1541
  18. Kaski JC, Consuegra-Sanchez L, Fernandez-Berges DJ, et al. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis. 2008;201:176–183
  19. Nathan CF. Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon-γ. In:  Gresser I,  Vilcek J editor. Interferon. vol. 7:London: Academic Press; 1986;p. 125–143
  20. Nathan CF, Prendergast TJ, Wiebe ME, et al. Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med. 1984;160:600–605
  21. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res. 1999;31:261–272
  22. Fuchs D, Baier-Bitterlich G, Wede I, Wachter H. Reactive oxygen and apoptosis. In:  Scandalios J editors. Oxidative stress and the molecular biology of antioxidant defenses. Cold Spring Harbor-New York: Cold Spring Harbor Laboratory Press; 1997;p. 139–167
  23. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress?. Anticancer Res. 1999;19:1721–1728
  24. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  25. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part I. Basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912–1916
  26. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part II. Animal and human studies. Circulation. 2003;108:2034–2040
  27. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. The association between pre-hypertension status and oxidative stress markers related to atherosclerotic disease: the ATTICA study. Atherosclerosis. 2007;192:169–176
  28. Praticò D. Antioxidants and endothelium protection. Atherosclerosis. 2005;181:215–224
  29. Kaliora AC, Dedoussis GV, Schmidt H. Dietary antioxidants in preventing atherogenesis. Atherosclerosis. 2006;187:1–17
  30. Winkelmann BR, März W, Boehm BO, et al. Rationale and design of the LURIC study: a resource for functional genomics; pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001;2:S1–S73
  31. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease Council on Cardiovascular Surgery American Heart Association. Circulation. 1975;51(4 Suppl):5–40
  32. Jaffé M. Über den Niederschlag, welchen Pikrinsäure in normalem Harn erzeugt und über eine neue Reaktion des Kreatinins. Z Physiol Chem. 1886;10:391–400
  33. Aebischer CP, Schierle J, Schuep W. Simultaneous determination of retinol, tocopherols, carotene, lycopene, and xanthophylls in plasma by means of reversed-phase high-performance liquid chromatography. Methods Enzymol. 1999;299:348–362
  34. Mason WD, Amick EN, Heft W. Analysis of ascorbic acid in human plasma and urine by HPLC with electrochemical detection. Anal Lett. 1980;13:817–824
  35. Sowell AL, Huff DL, Yeager PR, Caudill SP, Gunter EW. Retinol, alpha-tocopherol, lutein/zeaxanthin, beta-cryptoxanthin, lycopene, alpha-carotene, trans-beta-carotene, and four retinyl esters in serum determined simultaneously by reversed-phase HPLC with multiwavelength detection. Clin Chem. 1994;40:411–416
  36. Konstantino Y, Wolk R, Terra SG, Nguyen TT, Fryburg DA. Non-traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?. Acute Card Care. 2007;9:197–206
  37. Mann JF, Gerstein HC, Pogue J, Lonn E, Yusuf S. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. Am J Cardiovasc Drugs. 2002;2:157–162
  38. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med. 2004;256:308–315
  39. Schwedhelm E, Maas R, Troost R, Boger RH. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet. 2003;42:437–459
  40. Solichová D, Melichar B, Svobodová I, Bláha V, Zadák Z. Fluorescence analysis of antioxidant vitamins and neopterin in nonagenarians. Biomed Chromatogr. 1999;13:117–118
  41. Sattler W, Leblhuber F, Walli J, Widner B, Fuchs D. Cerebrospinal fluid levels of α-tocopherol and neopterin in patients with dementia. Pteridines. 1999;10:220–224
  42. Winklhofer-Roob BM, Ellemunter H, Frühwirth M, et al. Plasma vitamin C concentrations in patients with cystic fibrosis. Evidence of associations with lung inflammation. Am J Clin Nutr. 1997;65:1858–1866
  43. Weiss G, Fuchs D, Hausen A, et al. Neopterin modulates toxicity mediated by reactive oxygen and chlorine species. FEBS Lett. 1993;321:89–92
  44. Murr C, Baier-Bitterlich G, Fuchs D, et al. Effects of neopterin-derivatives on H2O2-induced luminol chemiluminescence: mechanistic aspects. Free Radic Biol Med. 1996;21:449–456
  45. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation associated production of neopterin derivatives in humans. Inflamm Res. 2003;52:313–321
  46. Balogh A, Mittermayr M, Schlager A, et al. Mechanism of neopterin-induced myocardial dysfunction in the isolated perfused rat heart. Biochim Biophys Acta. 2005;1724:17–22
  47. Herpfer I, Greilberger J, Ledinski G, Widner B, Fuchs D, Jürgens G. Neopterin and 7;8-dihydroneopterin interfere with low density lipoprotein oxidation mediated by peroxynitrite and/or cooper. Free Radic Res. 2002;36:509–520
  48. Cirillo P, Pacileo M, DE Rosa S, et al. Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. J Thromb Haemost. 2006;4:2248–2255
  49. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys. 1989;274:532–538
  50. Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins. Vitamins E and C beta-carotene and other carotenoids. Ann NY Acad Sci. 1992;669:7–20
  51. Tan PH, Sagoo P, Chan C, et al. Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol. 2005;174:7633–7644
  52. Wirleitner B, Schroecksnadel K, Winkler C, Schennach H, Fuchs D. Resveratrol suppresses interferon-gamma-induced biochemical pathways in human peripheral blood mononuclear cells in vitro. Immunol Lett. 2005;100:159–163
  53. Winkler C, Schroecksnadel K, Schennach H, Fuchs D. Vitamin C and E suppress mitogen-stimulated peripheral blood mononuclear cells in vitro. Int Arch Allergy Immunol. 2007;142:127–132
  54. Schroecksnadel K, Winkler C, Fischer B, Schennach H, Weiss G, Fuchs D. Antioxidants down-regulate Th1-type immune response in vitro. Drug Metabol Lett. 2007;1:166–171

PII: S0021-9150(08)00330-4

doi: 10.1016/j.atherosclerosis.2008.04.047

Atherosclerosis
Volume 202, Issue 2 , Pages 543-549 , February 2009

Article Tools

* Image Usage & Resolution